Trial Profile
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs TMX 049 (Primary)
- Indications Diabetic nephropathies; Proteinuria
- Focus Therapeutic Use
- Sponsors Teijin
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 19 Sep 2019 Results presented in the XORTX Therapeutics media release.
- 19 Sep 2019 Primary endpoint (Change in log-transformed urinary albumin-to-creatinine ratio (UACR)) has been met, according to the XORTX Therapeutics media release.